| Year |
Citation |
Score |
| 2023 |
Chiosis G, Digwal CS, Trepel JB, Neckers L. Structural and functional complexity of HSP90 in cellular homeostasis and disease. Nature Reviews. Molecular Cell Biology. PMID 37524848 DOI: 10.1038/s41580-023-00640-9 |
0.408 |
|
| 2021 |
Joshi S, Gomes ED, Wang T, Corben A, Taldone T, Gandu S, Xu C, Sharma S, Buddaseth S, Yan P, Chan LYL, Gokce A, Rajasekhar VK, Shrestha L, Panchal P, ... ... Chiosis G, et al. Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. Communications Biology. 4: 1333. PMID 34824367 DOI: 10.1038/s42003-021-02842-3 |
0.311 |
|
| 2021 |
Calvo-Vidal MN, Zamponi N, Krumsiek J, Stockslager MA, Revuelta MV, Phillip JM, Marullo R, Tikhonova E, Kotlov N, Patel J, Yang SN, Yang L, Taldone T, Thieblemont C, Leonard JP, ... ... Chiosis G, et al. Oncogenic HSP90 facilitates metabolic alterations in aggressive B-cell lymphomas. Cancer Research. PMID 34479963 DOI: 10.1158/0008-5472.CAN-21-2734 |
0.367 |
|
| 2021 |
Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, Yan L, De Leon JP, Croyle JA, Kaner J, Merugu S, Sharma S, MacDonald TY, Noorzad Z, Panchal P, ... ... Chiosis G, et al. Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. Npj Precision Oncology. 5: 44. PMID 34040147 DOI: 10.1038/s41698-021-00183-2 |
0.309 |
|
| 2020 |
Grbovic-Huezo O, Pitter KL, Lecomte N, Saglimbeni J, Askan G, Holm M, Melchor JP, Chandwani R, Joshi S, Haglund C, Iacobuzio-Donahue CA, Chiosis G, Tammela T, Leach SD. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 33199632 DOI: 10.1073/pnas.1920240117 |
0.327 |
|
| 2020 |
Yang J, Wang T, Zhao L, Rajasekhar VK, Joshi S, Andreou C, Pal S, Hsu HT, Zhang H, Cohen IJ, Huang R, Hendrickson RC, Miele MM, Pei W, Brendel MB, ... ... Chiosis G, et al. Gold/alpha-lactalbumin nanoprobes for the imaging and treatment of breast cancer. Nature Biomedical Engineering. 4: 686-703. PMID 32661307 DOI: 10.1038/S41551-020-0584-Z |
0.305 |
|
| 2020 |
Yan P, Patel HJ, Sharma S, Corben A, Wang T, Panchal P, Yang C, Sun W, Araujo TL, Rodina A, Joshi S, Robzyk K, Gandu S, White JR, de Stanchina E, ... ... Chiosis G, et al. Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. Cell Reports. 31: 107840. PMID 32610141 DOI: 10.1016/J.Celrep.2020.107840 |
0.403 |
|
| 2020 |
Merugu S, Sharma S, Kaner J, Digwal C, Sugita M, Joshi S, Taldone T, Guzman ML, Chiosis G. Chemical probes and methods for single-cell detection and quantification of epichaperomes in hematologic malignancies. Methods in Enzymology. 639: 289-311. PMID 32475406 DOI: 10.1016/Bs.Mie.2020.04.057 |
0.338 |
|
| 2020 |
Dunphy MP, Pressl C, Pillarsetty N, Grkovski M, Modi S, Jhaveri K, Norton L, Beattie BJ, Zanzonico PB, Zatorska D, Taldone T, Ochiana SO, Uddin MM, Burnazi EM, Lyashchenko SK, ... ... Chiosis G, et al. First-in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32366671 DOI: 10.1158/1078-0432.Ccr-19-3704 |
0.336 |
|
| 2020 |
Yan P, Wang T, Guzman ML, Peter RI, Chiosis G. Chaperome Networks - Redundancy and Implications for Cancer Treatment. Advances in Experimental Medicine and Biology. 1243: 87-99. PMID 32297213 DOI: 10.1007/978-3-030-40204-4_6 |
0.338 |
|
| 2020 |
Pechalrieu D, Assemat F, Halby L, Marcellin M, Yan P, Chaoui K, Sharma S, Chiosis G, Burlet-Schiltz O, Arimondo PB, Lopez M. Bisubstrate-type chemical probes identify GRP94 as a potential target of cytosine-containing adenosine analogs. Acs Chemical Biology. PMID 32191434 DOI: 10.1021/Acschembio.9B00965 |
0.367 |
|
| 2020 |
Inda MC, Joshi S, Wang T, Bolaender A, Gandu S, Koren Iii J, Che AY, Taldone T, Yan P, Sun W, Uddin M, Panchal P, Riolo M, Shah S, Barlas A, ... ... Chiosis G, et al. The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction. Nature Communications. 11: 319. PMID 31949159 DOI: 10.1038/S41467-019-14082-5 |
0.321 |
|
| 2020 |
Chen L, Liu Y, Becher A, Diepold K, Schmid E, Fehn A, Brunner C, Rouhi A, Chiosis G, Cronauer M, Seufferlein T, Azoitei N. Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2. Carcinogenesis. PMID 31917403 DOI: 10.1093/Carcin/Bgaa001 |
0.514 |
|
| 2019 |
Pillarsetty N, Jhaveri K, Taldone T, Caldas-Lopes E, Punzalan B, Joshi S, Bolaender A, Uddin MM, Rodina A, Yan P, Ku A, Ku T, Shah SK, Lyashchenko S, Burnazi E, ... ... Chiosis G, et al. Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer Cell. PMID 31668946 DOI: 10.1016/J.Ccell.2019.09.007 |
0.403 |
|
| 2019 |
Osmanbeyoglu HU, Shimizu F, Rynne-Vidal A, Alonso-Curbelo D, Chen HA, Wen HY, Yeung TL, Jelinic P, Razavi P, Lowe SW, Mok SC, Chiosis G, Levine DA, Leslie CS. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. Nature Communications. 10: 4369. PMID 31554806 DOI: 10.1038/S41467-019-12291-6 |
0.371 |
|
| 2019 |
Huck JD, Que NLS, Immormino RM, Shrestha L, Taldone T, Chiosis G, Gewirth DT. NECA derivatives exploit the paralog-specific properties of the Site 3 side pocket of Grp94, the ER Hsp90. The Journal of Biological Chemistry. PMID 31501246 DOI: 10.1074/Jbc.Ra119.009960 |
0.412 |
|
| 2019 |
Taldone T, Wang T, Rodina A, Pillarsetty NVK, Digwal CS, Sharma S, Yan P, Joshi S, Pagare PP, Bolaender A, Roboz GJ, Guzman ML, Chiosis G. A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond. Cold Spring Harbor Perspectives in Biology. PMID 30936118 DOI: 10.1101/Cshperspect.A034116 |
0.47 |
|
| 2019 |
Bekeschus S, Lippert M, Diepold K, Chiosis G, Seufferlein T, Azoitei N. Physical plasma-triggered ROS induces tumor cell death upon cleavage of HSP90 chaperone. Scientific Reports. 9: 4112. PMID 30858416 DOI: 10.1038/S41598-019-38580-0 |
0.539 |
|
| 2019 |
Huck JD, Que NLS, Sharma S, Taldone T, Chiosis G, Gewirth DT. Structures of Hsp90 alpha and Hsp90 beta bound to a purine-scaffold inhibitor reveal an exploitable residue for drug selectivity. Proteins. 87: 869-877. DOI: 10.2210/Pdb6N8Y/Pdb |
0.366 |
|
| 2019 |
Kaner JD, Tavakkoli M, Toudic L, Stevens BM, Jordan CT, Taldone T, Chiosis G, Ritchie EK, Desai P, Samuel MB, Lee S, Roboz GJ, Guzman ML. PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71 Blood. 134: 3935-3935. DOI: 10.1182/Blood-2019-128276 |
0.348 |
|
| 2019 |
Hinze L, Schreek S, Zeug A, Ponimaskin E, Labrosse R, Degar J, Chiosis G, Pai S, Stevenson KE, Neuberg DS, Bornhauser B, Bourquin J, Stanulla M, Gutierrez A. Inducible Phase Separation of GSK3α As a Mechanism for Asparaginase Resistance in Acute Leukemias Blood. 134: 169-169. DOI: 10.1182/Blood-2019-126633 |
0.379 |
|
| 2019 |
Caldas Lopes E, Wang T, Jayabalan DS, Taldone T, Monge J, Contreras J, Winnie Y, Trujillo V, Palak P, Lombardi N, Sahil S, Chander D, Coleman M, Chiosis G, Niesvizky R, et al. Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma Blood. 134: 4399-4399. DOI: 10.1182/Blood-2019-125267 |
0.399 |
|
| 2019 |
Tavakkoli M, Kaner JD, Sahil S, Taldone T, Merugu S, Chiosis G, Roboz GJ, Guzman ML. Epichaperome Abundance Predicts Response to the Epichaperome Inhibitor, Puh-71, in Acute Myeloid Leukemia Blood. 134: 5145-5145. DOI: 10.1182/Blood-2019-125175 |
0.317 |
|
| 2019 |
Jhaveri K, Dunphy M, Wang R, Comen E, Fornier M, Moynahan M, Bromberg J, Ma W, Patil S, Taldone T, Rodina A, Sterlin V, Khoshi S, Lewis J, Norton L, ... Chiosis G, et al. Abstract P6-20-03: Tumor epichaperome expression using 124I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-20-03 |
0.351 |
|
| 2019 |
Lopes EC, Wang T, Jayabalan D, Monge J, Taldone T, Contreras J, Yip W, Panchal P, Sharma S, Digwal C, Chiosis G, Niesvizky R, Guzman M. Biomarker based targeting of the epichaperome as a novel therapeutic approach for Multiple Myeloma (MM) Clinical Lymphoma Myeloma and Leukemia. 19: e126. DOI: 10.1016/J.Clml.2019.09.208 |
0.314 |
|
| 2018 |
Wang T, Rodina A, Dunphy MP, Corben A, Modi S, Guzman ML, Gewirth DT, Chiosis G. Chaperome heterogeneity and its implications for cancer study and treatment. The Journal of Biological Chemistry. PMID 30409908 DOI: 10.1074/Jbc.Rev118.002811 |
0.426 |
|
| 2018 |
Kourtis N, Lazaris C, Hockemeyer K, Balandrán JC, Jimenez AR, Mullenders J, Gong Y, Trimarchi T, Bhatt K, Hu H, Shrestha L, Ambesi-Impiombato A, Kelliher M, Paietta E, Chiosis G, et al. Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia. Nature Medicine. PMID 30038221 DOI: 10.1038/S41591-018-0105-8 |
0.378 |
|
| 2018 |
Joshi S, Wang T, Araujo TLS, Sharma S, Brodsky JL, Chiosis G. Adapting to stress - chaperome networks in cancer. Nature Reviews. Cancer. PMID 29795326 DOI: 10.1038/S41568-018-0020-9 |
0.352 |
|
| 2018 |
Roboz GJ, Sugita M, Mosquera JM, Wilkes DC, Nataraj S, Jimenez-Flores RA, Bareja R, Yan L, Eng KW, Croyle JA, MacDonald TY, Noorzad Z, Pancirer D, Cheng S, Xiang JZ, ... ... Chiosis G, et al. Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia Blood. 132: 1435-1435. DOI: 10.1182/Blood-2018-99-118764 |
0.416 |
|
| 2017 |
Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, Weirich G, Panchal P, Gopalan A, Zurita J, Achilefu S, Chiosis G, Ponomarev V, Schwaiger M, Carver BS, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. The Journal of Experimental Medicine. PMID 29141866 DOI: 10.1084/Jem.20171052 |
0.318 |
|
| 2017 |
Liu Y, Steinestel K, Rouhi A, Armacki M, Diepold K, Chiosis G, Simmet T, Seufferlein T, Azoitei N. STK33 participates to HSP90-supported angiogenic program in hypoxic tumors by regulating HIF-1α/VEGF signaling pathway. Oncotarget. 8: 77474-77488. PMID 29100402 DOI: 10.18632/Oncotarget.20535 |
0.483 |
|
| 2017 |
Weidenauer L, Wang T, Joshi S, Chiosis G, Quadroni MR. Proteomic interrogation of HSP90 and insights for medical research. Expert Review of Proteomics. PMID 28990809 DOI: 10.1080/14789450.2017.1389649 |
0.541 |
|
| 2017 |
Giulino-Roth L, Van Besien HJ, Dalton T, Totonchy JE, Rodina A, Taldone T, Bolaender A, Erdjument-Bromage H, Sadek J, Chadburn A, Barth MJ, Dela Cruz FS, Rainey A, Kung AL, Chiosis G, et al. Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma. Molecular Cancer Therapeutics. PMID 28619753 DOI: 10.1158/1535-7163.Mct-16-0848 |
0.557 |
|
| 2017 |
Guo A, Lu P, Lee J, Zhen C, Chiosis G, Wang YL. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. Oncogene. PMID 28114285 DOI: 10.1038/Onc.2016.494 |
0.502 |
|
| 2016 |
Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, ... ... Chiosis G, et al. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. PMID 27706135 DOI: 10.1038/Nature19807 |
0.45 |
|
| 2016 |
Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, Koren J, Chiosis G, Sabatino D. RNAi screening of the Glucose Regulated Chaperones in Cancer with Self-Assembled siRNA Nanostructures. Nano Letters. PMID 27669096 DOI: 10.1021/Acs.Nanolett.6B02274 |
0.348 |
|
| 2016 |
Chiosis G. Editorial (Thematic Issue: Heat Shock Proteins in Disease - From Molecular Mechanisms to Therapeutics). Current Topics in Medicinal Chemistry. 16: 2727-8. PMID 27549859 DOI: 10.2174/156802661625160816181132 |
0.406 |
|
| 2016 |
Chiosis G. Editorial: Heat Shock Protein in Disease - From Molecular Mechanisms to Therapeutics. Current Topics in Medicinal Chemistry. PMID 27142687 DOI: 10.2174/156802606777812022 |
0.409 |
|
| 2016 |
Ansa-Addo EA, Thaxton J, Hong F, Wu BX, Zhang Y, Fugle CW, Metelli A, Riesenberg B, Williams K, Gewirth DT, Chiosis G, Liu B, Li Z. Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94. Current Topics in Medicinal Chemistry. PMID 27072698 DOI: 10.2174/1568026616666160413141613 |
0.39 |
|
| 2016 |
Shrestha L, Patel HJ, Chiosis G. Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease. Cell Chemical Biology. 23: 158-72. PMID 26933742 DOI: 10.1016/J.Chembiol.2015.12.006 |
0.492 |
|
| 2016 |
Taldone T, Zatorska D, Ochiana SO, Smith-Jones P, Koziorowski J, Dunphy MP, Zanzonico P, Bolaender A, Lewis JS, Larson SM, Chiosis G, Pillarsetty NV. Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71. Journal of Labelled Compounds & Radiopharmaceuticals. PMID 26806023 DOI: 10.1002/Jlcr.3369 |
0.496 |
|
| 2016 |
Wang YL, Lu P, Lee J, Zhen CJ, Chiosis G, Guo A. HSP90 Stabilizes B-Cell Receptor Kinases in a Multi-Client Interactome: PU-H71 Induces CLL Apoptosis in a Cytoprotective Microenvironment Blood. 128: 5105-5105. DOI: 10.1182/Blood.V128.22.5105.5105 |
0.515 |
|
| 2015 |
Zong H, Gozman A, Caldas-Lopes E, Taldone T, Sturgill E, Brennan S, Ochiana SO, Gomes-DaGama EM, Sen S, Rodina A, Koren J, Becker MW, Rudin CM, Melnick A, Levine RL, ... ... Chiosis G, et al. A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell Reports. PMID 26628369 DOI: 10.1016/J.Celrep.2015.10.073 |
0.409 |
|
| 2015 |
Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, et al. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood. PMID 26603836 DOI: 10.1182/Blood-2015-05-645069 |
0.478 |
|
| 2015 |
Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. The Journal of Clinical Investigation. 2015. PMID 26529251 DOI: 10.1172/Jci80714 |
0.419 |
|
| 2015 |
Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Sanchez Martin M, Dong L, Tallman MS, Paietta E, Wang K, He J, Lipson D, Stephens P, Miller V, Rowe JM, ... ... Chiosis G, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. PMID 26443624 DOI: 10.1182/Blood-2015-03-635821 |
0.503 |
|
| 2015 |
Salinas B, Irwin CP, Kossatz S, Bolaender A, Chiosis G, Pillarsetty N, Weber WA, Reiner T. Radioiodinated PARP1 tracers for glioblastoma imaging. Ejnmmi Research. 5: 123. PMID 26337803 DOI: 10.1186/S13550-015-0123-1 |
0.358 |
|
| 2015 |
Needham PG, Patel HJ, Chiosis G, Thibodeau PH, Brodsky JL. Mutations in the Yeast Hsp70, Ssa1, at P417 Alter ATP Cycling, Interdomain Coupling, and Specific Chaperone Functions. Journal of Molecular Biology. PMID 25913688 DOI: 10.1016/J.Jmb.2015.04.010 |
0.386 |
|
| 2015 |
Patel HJ, Patel PD, Ochiana SO, Yan P, Sun W, Patel MR, Shah SK, Tramentozzi E, Brooks J, Bolaender A, Shrestha L, Stephani R, Finotti P, Leifer C, Li Z, ... ... Chiosis G, et al. Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94. Journal of Medicinal Chemistry. 58: 3922-43. PMID 25901531 DOI: 10.1021/Acs.Jmedchem.5B00197 |
0.428 |
|
| 2015 |
Rachidi S, Sun S, Wu BX, Jones E, Drake RR, Ogretmen B, Cowart LA, Clarke CJ, Hannun YA, Chiosis G, Liu B, Li Z. Endoplasmic reticulum heat shock protein gp96 maintains liver homeostasis and promotes hepatocellular carcinogenesis. Journal of Hepatology. 62: 879-88. PMID 25463537 DOI: 10.1016/J.Jhep.2014.11.010 |
0.387 |
|
| 2015 |
Gerecitano JF, Modi S, Rampal R, Drilon AE, Fury MG, Gounder MM, Harding JJ, Hyman DM, Varghese AM, Voss MH, France FO, Taldone T, Gomes DaGama E, Uddin M, Chiosis G, et al. Phase I trial of the HSP-90 inhibitor PU-H71. Journal of Clinical Oncology. 33: 2537-2537. DOI: 10.1200/Jco.2015.33.15_Suppl.2537 |
0.309 |
|
| 2015 |
Giulino Roth L, van Besien H, Rodina A, Taldone T, Erdjument-Bromage H, Barth MJ, Chiosis G, Cesarman E. Targeting the Hsp90 Oncoproteome in Burkitt Lymphoma Blood. 126: 592-592. DOI: 10.1182/Blood.V126.23.592.592 |
0.526 |
|
| 2015 |
Guo A, Lu P, Zhen C, Chiosis G, Wang YL. An HSP90 Inhibitor, PU-H71, Antagonizes Stroma-Induced Pro-Survival Effects in CLL through Its Inhibition of Multi-Component B-Cell Receptor Signaling Pathway Blood. 126: 5289-5289. DOI: 10.1182/Blood.V126.23.5289.5289 |
0.468 |
|
| 2015 |
Zong H, Taldone T, Roboz GJ, Chiosis G, Guzman ML. A Hyperactive Signalosome Results in High Sensitivity to HSP90 Inhibitors in AML Blood. 126: 2567-2567. DOI: 10.1182/Blood.V126.23.2567.2567 |
0.497 |
|
| 2015 |
Chiosis G. Abstract SY30-02: Understanding the proteome through the chaperome: From mechanisms to diagnostics and drugs Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Sy30-02 |
0.382 |
|
| 2015 |
Taldone T, Pillarsetty N, Dunphy MP, Gerecitano JF, Caldas-Lopes E, Beattie B, Peter RI, Kang Y, Rodina A, Yan P, Gomes EMD, Bolaender A, Pressl C, Punzalan B, Ku A, ... ... Chiosis G, et al. Abstract 5444: Development of a noninvasive assay to determine drug concentration in tumor during hsp90 inhibitor therapy Cancer Research. 75: 5444-5444. DOI: 10.1158/1538-7445.Am2015-5444 |
0.49 |
|
| 2015 |
Yan P, Patel H, Patel P, Ochiana S, Sun W, Shah S, Finotti P, Leifer C, Li Z, Gewirth D, Taldone T, Chiosis G. Abstract 4716: Tumor-specific regulation of receptor tyrosine kinases by Grp94 Cancer Research. 75: 4716-4716. DOI: 10.1158/1538-7445.Am2015-4716 |
0.442 |
|
| 2015 |
Ochiana SO, Taldone T, Patel HJ, Patel P, Pengrong Y, Sun W, Rodina A, Shah S, Gewirth DT, Chiosis G. Abstract 2831: Development of selective GRP94 inhibitors for the treatment of cancer Cancer Research. 75: 2831-2831. DOI: 10.1158/1538-7445.Am2015-2831 |
0.503 |
|
| 2015 |
Koren J, Xu C, Rodina A, Shrestha L, Taldone T, Chiosis G. Abstract 1740: Allosteric Hsp70-family inhibitors as targeted anticancer therapeutics Cancer Research. 75: 1740-1740. DOI: 10.1158/1538-7445.Am2015-1740 |
0.581 |
|
| 2015 |
Rodina AA, Taldone T, Kang Y, Patel P, Koren J, Yan P, Gomes ED, Yang C, Patel M, Shrestha L, Ochiana S, Maharaj R, Gozman A, Cox M, Erdjument-Bromage H, ... ... Chiosis G, et al. Abstract 1733: Development of chemical tools to study the endogenous Hsp70 interactome in malignant cells Cancer Research. 75: 1733-1733. DOI: 10.1158/1538-7445.Am2015-1733 |
0.592 |
|
| 2015 |
Azoitei N, Becher A, Diepold K, Bobrovich S, Brunner C, Chiosis G, Fröhling S, Johan vL, Scholl C, Seufferlein T. Abstract 1435: Role of PRKD2 in HSP90- and hypoxia-mediated epithelial-to-mesenchymal transition Cancer Research. 75: 1435-1435. DOI: 10.1158/1538-7445.Am2015-1435 |
0.523 |
|
| 2015 |
Chiosis G. O3-04-01: Targeting a stress-associated hsp90 complex as a novel therapeutic strategy to downregulate toxic tau in Alzheimer's disease Alzheimer's & Dementia. 11: P225-P226. DOI: 10.1016/J.Jalz.2015.07.254 |
0.343 |
|
| 2014 |
Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, Chiosis G, Chung YR, Pandey S, van den Brink MR, Armstrong SA, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America. 111: E5401-10. PMID 25516983 DOI: 10.1073/Pnas.1407792111 |
0.396 |
|
| 2014 |
Corben AD, Uddin MM, Crawford B, Farooq M, Modi S, Gerecitano J, Chiosis G, Alpaugh ML. Ex vivo treatment response of primary tumors and/or associated metastases for preclinical and clinical development of therapeutics. Journal of Visualized Experiments : Jove. e52157. PMID 25350385 DOI: 10.3791/52157 |
0.378 |
|
| 2014 |
Chan CT, Qi J, Smith W, Paranol R, Mazitschek R, West N, Reeves R, Chiosis G, Schreiber SL, Bradner JE, Paulmurugan R, Gambhir SS. Syntheses and discovery of a novel class of cinnamic hydroxamates as histone deacetylase inhibitors by multimodality molecular imaging in living subjects. Cancer Research. 74: 7475-86. PMID 25320008 DOI: 10.1158/0008-5472.Can-14-0197 |
0.44 |
|
| 2014 |
Azoitei N, Diepold K, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Koren J, Fröhling S, Scholl C, Seufferlein T. HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization. Cancer Research. 74: 7125-36. PMID 25297628 DOI: 10.1158/0008-5472.Can-14-1017 |
0.504 |
|
| 2014 |
Taldone T, Ochiana SO, Patel PD, Chiosis G. Selective targeting of the stress chaperome as a therapeutic strategy. Trends in Pharmacological Sciences. 35: 592-603. PMID 25262919 DOI: 10.1016/J.Tips.2014.09.001 |
0.364 |
|
| 2014 |
Rodina A, Taldone T, Kang Y, Patel PD, Koren J, Yan P, DaGama Gomes EM, Yang C, Patel MR, Shrestha L, Ochiana SO, Santarossa C, Maharaj R, Gozman A, Cox MB, ... ... Chiosis G, et al. Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. Acs Chemical Biology. 9: 1698-705. PMID 24934503 DOI: 10.1021/Cb500256U |
0.567 |
|
| 2014 |
Taldone T, Patel HJ, Bolaender A, Patel MR, Chiosis G. Protein chaperones: a composition of matter review (2008 - 2013). Expert Opinion On Therapeutic Patents. 24: 501-18. PMID 24742089 DOI: 10.1517/13543776.2014.887681 |
0.519 |
|
| 2014 |
Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM, Koren J, Modi S, Chiosis G. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opinion On Investigational Drugs. 23: 611-28. PMID 24669860 DOI: 10.1517/13543784.2014.902442 |
0.526 |
|
| 2014 |
Taldone T, Kang Y, Patel HJ, Patel MR, Patel PD, Rodina A, Patel Y, Gozman A, Maharaj R, Clement CC, Lu A, Young JC, Chiosis G. Heat shock protein 70 inhibitors. 2. 2,5'-thiodipyrimidines, 5-(phenylthio)pyrimidines, 2-(pyridin-3-ylthio)pyrimidines, and 3-(phenylthio)pyridines as reversible binders to an allosteric site on heat shock protein 70. Journal of Medicinal Chemistry. 57: 1208-24. PMID 24548239 DOI: 10.1021/Jm401552Y |
0.531 |
|
| 2014 |
Kang Y, Taldone T, Patel HJ, Patel PD, Rodina A, Gozman A, Maharaj R, Clement CC, Patel MR, Brodsky JL, Young JC, Chiosis G. Heat shock protein 70 inhibitors. 1. 2,5'-thiodipyrimidine and 5-(phenylthio)pyrimidine acrylamides as irreversible binders to an allosteric site on heat shock protein 70. Journal of Medicinal Chemistry. 57: 1188-207. PMID 24548207 DOI: 10.1021/Jm401551N |
0.571 |
|
| 2014 |
Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, Qi J, Kleppe M, Patel HJ, Shah SK, Taldone T, Bradner JE, Chiosis G, Levine RL. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. 123: 2075-83. PMID 24470592 DOI: 10.1182/Blood-2014-01-547760 |
0.45 |
|
| 2014 |
Ambati SR, Lopes EC, Kosugi K, Mony U, Zehir A, Shah SK, Taldone T, Moreira AL, Meyers PA, Chiosis G, Moore MA. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma. Molecular Oncology. 8: 323-36. PMID 24388362 DOI: 10.1016/J.Molonc.2013.12.005 |
0.455 |
|
| 2014 |
Carman A, Kishinevsky S, Koren J, Luo W, Chiosis G. Regulatory chaperone complexes in neurodegenerative diseases: a perspective on therapeutic intervention. Current Alzheimer Research. 11: 59-68. PMID 24251390 DOI: 10.2174/1567205010666131119233044 |
0.406 |
|
| 2014 |
Fernando TM, Yang SN, Huang C, Chiosis G, Cerchietti L, Melnick AM. BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain Blood. 124: 567-567. DOI: 10.1182/Blood.V124.21.567.567 |
0.415 |
|
| 2014 |
Calvo-Vidal N, Patel J, Krumsiek J, Dupont T, Goldstein R, Yang SN, Melnick A, Chiosis G, Cerchietti L. Hsp90 at the Hub of Metabolic Homeostasis in Malignant B Cells Blood. 124: 1764-1764. DOI: 10.1182/Blood.V124.21.1764.1764 |
0.504 |
|
| 2014 |
Azoitei N, Diepold K, Genze F, Rouhi A, Brobovich S, Froehling S, Chiosis G, Brunner C, Lint Jv, Cronauer M, Scholl C, Seufferlein T. Abstract 5129: Role of PRKD2 in HSP90 inhibition-mediated suppression of cancer growth Cancer Research. 74: 5129-5129. DOI: 10.1158/1538-7445.Am2014-5129 |
0.568 |
|
| 2014 |
Yan P, Patel H, Yang C, Taldone T, Chiosis G. Abstract 3329: Investigations into the tumor specific regulation of HER2 by Grp94 in breast cancer Cancer Research. 74: 3329-3329. DOI: 10.1158/1538-7445.Am2014-3329 |
0.486 |
|
| 2014 |
Azoitei N, Diepold K, Brobovich S, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Fröhling S, Scholl C, Seufferlein T. Protein kinase D2 modulates tumor growth and tumor angiogenic programme induced by heat shock protein 90 Zeitschrift FüR Gastroenterologie. 52. DOI: 10.1055/S-0034-1386210 |
0.408 |
|
| 2014 |
Goldstein R, Chiosis G, Cerchietti L, Melnick A. 563 Hsp90 pharmacoproteomics: Harnessing pleiotropy for therapeutic synergy European Journal of Cancer. 50: 182. DOI: 10.1016/S0959-8049(14)70689-6 |
0.381 |
|
| 2013 |
Carman A, Kishinevsky S, Koren J, Lou W, Chiosis G. Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention. Journal of Alzheimer's Disease & Parkinsonism. 2013. PMID 25258700 DOI: 10.4172/2161-0460.S10-007 |
0.451 |
|
| 2013 |
Rodina A, Patel PD, Kang Y, Patel Y, Baaklini I, Wong MJ, Taldone T, Yan P, Yang C, Maharaj R, Gozman A, Patel MR, Patel HJ, Chirico W, Erdjument-Bromage H, ... ... Chiosis G, et al. Identification of an allosteric pocket on human hsp70 reveals a mode of inhibition of this therapeutically important protein. Chemistry & Biology. 20: 1469-80. PMID 24239008 DOI: 10.1016/J.Chembiol.2013.10.008 |
0.556 |
|
| 2013 |
Shahinas D, Folefoc A, Taldone T, Chiosis G, Crandall I, Pillai DR. A purine analog synergizes with chloroquine (CQ) by targeting Plasmodium falciparum Hsp90 (PfHsp90). Plos One. 8: e75446. PMID 24098696 DOI: 10.1371/Journal.Pone.0075446 |
0.353 |
|
| 2013 |
Hua Y, White-Gilbertson S, Kellner J, Rachidi S, Usmani SZ, Chiosis G, Depinho R, Li Z, Liu B. Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma Clinical Cancer Research. 19: 6242-6251. PMID 24077352 DOI: 10.1158/1078-0432.Ccr-13-2083 |
0.342 |
|
| 2013 |
Patel PD, Yan P, Seidler PM, Patel HJ, Sun W, Yang C, Que NS, Taldone T, Finotti P, Stephani RA, Gewirth DT, Chiosis G. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nature Chemical Biology. 9: 677-84. PMID 23995768 DOI: 10.1038/Nchembio.1335 |
0.524 |
|
| 2013 |
Taldone T, Patel PD, Patel M, Patel HJ, Evans CE, Rodina A, Ochiana S, Shah SK, Uddin M, Gewirth D, Chiosis G. Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series. Journal of Medicinal Chemistry. 56: 6803-18. PMID 23965125 DOI: 10.1021/Jm400619B |
0.432 |
|
| 2013 |
Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R, Melnick A, Cerchietti L, Chiosis G, Wang YL, Cesarman E. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 122: 2837-47. PMID 23943653 DOI: 10.1182/Blood-2013-01-479972 |
0.49 |
|
| 2013 |
Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors. Oncotarget. 4: 1065-74. PMID 23867252 DOI: 10.18632/Oncotarget.1099 |
0.556 |
|
| 2013 |
Taldone T, Rodina A, Dagama Gomes EM, Riolo M, Patel HJ, Alonso-Sabadell R, Zatorska D, Patel MR, Kishinevsky S, Chiosis G. Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes. Beilstein Journal of Organic Chemistry. 9: 544-56. PMID 23616796 DOI: 10.3762/Bjoc.9.60 |
0.499 |
|
| 2013 |
Chiosis G, Dickey CA, Johnson JL. A global view of Hsp90 functions. Nature Structural & Molecular Biology. 20: 1-4. PMID 23288357 DOI: 10.1038/Nsmb.2481 |
0.44 |
|
| 2013 |
Lisi L, McGuire S, Sharp A, Chiosis G, Navarra P, Feinstein DL, Dello Russo C. The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE. Journal of Neuroimmunology. 255: 1-7. PMID 23123171 DOI: 10.1016/J.Jneuroim.2012.10.008 |
0.421 |
|
| 2013 |
Taldone T, Zatorska D, Patel HJ, Sun W, Patel MR, Chiosis G. Preparation of a diverse purine-scaffold library via one-step palladium catalyzed cross-coupling Heterocycles. 87: 91-113. DOI: 10.3987/Com-12-12613 |
0.331 |
|
| 2013 |
Ambati SR, Caldas Lopes E, Kosugi K, Mony U, Zehir A, Moreira AL, Meyers PA, Chiosis G, Moore MA. Activity of PU-H71, a novel HSP90 inhibitor, and bortezomib in Ewing sarcoma preclinical models. Journal of Clinical Oncology. 31: 3101-3101. DOI: 10.1200/Jco.2013.31.15_Suppl.3101 |
0.475 |
|
| 2013 |
Gerecitano JF, Modi S, Gajria D, Taldone T, Alpaugh M, Gomes DaGama E, Uddin M, Chiosis G, Lewis JS, Larson SM, Pillarsetty NVK, Jhaveri KL, Krichevsky B, Chen MH, Dixit P, et al. Using 124I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71. Journal of Clinical Oncology. 31: 11076-11076. DOI: 10.1200/Jco.2013.31.15_Suppl.11076 |
0.307 |
|
| 2013 |
Riolo M, Modi S, Corben A, Hudis C, Alpaugh M, Chiosis G. Abstract 5598: A comprehensive study to analyze tumor sensitivity to HSP90 inhibition therapy. Cancer Research. 73: 5598-5598. DOI: 10.1158/1538-7445.Am2013-5598 |
0.521 |
|
| 2013 |
Ambati SR, Lopes EC, Mony U, Kosugi K, Moreira A, Meyers P, Chiosis G, Moore M. Abstract 2752: Novel inhibitor of HSP90- PU-H71 exhibits significant activity in Ewing sarcoma pre-clinical models. Cancer Research. 73: 2752-2752. DOI: 10.1158/1538-7445.Am2013-2752 |
0.503 |
|
| 2013 |
Goldstein RL, Cerchietti LC, Chiosis G, Melnick A. Abstract 2045: Oncoproteomic analysis of diffuse large B cell lymphomas reveals rationale for combination treatments. Cancer Research. 73: 2045-2045. DOI: 10.1158/1538-7445.Am2013-2045 |
0.496 |
|
| 2013 |
Koren J, Inda MC, Riolo M, Uddin M, Alonso-Sabadell R, Chiosis G. P1-402: Blood-brain-barrier-permeable Hsp90 inhibitor reduces soluble tau burden in a mouse model of Alzheimer's disease Alzheimer's & Dementia. 9: P305-P305. DOI: 10.1016/J.Jalz.2013.05.630 |
0.308 |
|
| 2012 |
Chan CT, Reeves RE, Geller R, Yaghoubi SS, Hoehne A, Solow-Cordero DE, Chiosis G, Massoud TF, Paulmurugan R, Gambhir SS. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects. Proceedings of the National Academy of Sciences of the United States of America. 109: E2476-85. PMID 22895790 DOI: 10.1073/Pnas.1205459109 |
0.55 |
|
| 2012 |
Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, ... ... Chiosis G, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature. 489: 155-9. PMID 22820254 DOI: 10.1038/Nature11303 |
0.402 |
|
| 2012 |
Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, et al. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. The Journal of Experimental Medicine. 209: 697-711. PMID 22451720 DOI: 10.1084/Jem.20111910 |
0.545 |
|
| 2012 |
Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochimica Et Biophysica Acta. 1823: 742-55. PMID 22062686 DOI: 10.1016/J.Bbamcr.2011.10.008 |
0.563 |
|
| 2012 |
Levine RL, Koppikar P, Marubayashi S, Bhagwat N, Taldone T, Park CY, Chiosis G. Combination Therapy Using JAK2 and HSP90 Inhibitors Increased Efficacy in Myelofibrosis in Vivo Blood. 120: 805-805. DOI: 10.1182/Blood.V120.21.805.805 |
0.406 |
|
| 2012 |
Lopes EC, Correa FM, Shen L, Shieh J, Taldone T, Chiosis G, Moore MA. Anti-Apoptotic Bcl2 and Bcl-Xl Proteins Involved in Stroma-Induced Drug Tolerance to Hsp70 and Hsp90 Inhibitors in Leukemia and B-Cell Lymphoma Blood. 120: 4900-4900. DOI: 10.1182/Blood.V120.21.4900.4900 |
0.485 |
|
| 2012 |
Sharma KK, Rico JF, Becker MW, Roboz GJ, Chiosis G, Guzman ML. HSP70 Inhibitor, YK5, Synergizes with Chemotherapeutic Agents and Prevents Chemoresistance in Acute Myelogenous Leukemia (AML). Blood. 120: 2476-2476. DOI: 10.1182/Blood.V120.21.2476.2476 |
0.494 |
|
| 2012 |
Nayar U, Lu P, Vider J, Goldstein RL, Ballon G, Cerchietti L, Chiosis G, Wang YL, Cesarman E. Abstract 4829: A purine scaffold Hsp90 inhibitor has antitumor activity in KSHV-associated malignancies by suppressing vFLIP Cancer Research. 72: 4829-4829. DOI: 10.1158/1538-7445.Am2012-4829 |
0.537 |
|
| 2012 |
Taldone T, Patel PD, Kang Y, Rodina A, Talele TT, Chiosis G. Abstract 3895: Rational design of small molecule inhibitors that bind to an allosteric pocket on human heat shock protein 70 (Hsp70) Cancer Research. 72: 3895-3895. DOI: 10.1158/1538-7445.Am2012-3895 |
0.543 |
|
| 2012 |
Rodina A, Moulick K, Ahn J, Zong H, Cerchietti L, DaGama EG, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu L, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... ... Chiosis G, et al. Abstract 3029: Biochemical evidence towards the existence of an oncogenic Hsp90 complex Cancer Research. 72: 3029-3029. DOI: 10.1158/1538-7445.Am2012-3029 |
0.825 |
|
| 2012 |
Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Döhner H, Chiosis G, Glimm H, Fröhling S, et al. Abstract 2773: HSP90 inhibitors target KRAS mutant human tumors through degradation of STK33 Cancer Research. 72: 2773-2773. DOI: 10.1158/1538-7445.Am2012-2773 |
0.547 |
|
| 2012 |
Gomes-DaGama EM, Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Lopes-Vazquez MEC, Beebe K, Perna F, Katerina C, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... ... Chiosis G, et al. Abstract 1263: Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90 Cancer Research. 72: 1263-1263. DOI: 10.1158/1538-7445.Am2012-1263 |
0.81 |
|
| 2011 |
Patel HJ, Modi S, Chiosis G, Taldone T. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opinion On Drug Discovery. 6: 559-587. PMID 22400044 DOI: 10.1517/17460441.2011.563296 |
0.56 |
|
| 2011 |
Usmani SZ, Chiosis G. HSP90 inhibitors as therapy for multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia. 11: S77-81. PMID 22035754 DOI: 10.1016/J.Clml.2011.03.027 |
0.536 |
|
| 2011 |
Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, ... ... Chiosis G, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chemical Biology. 7: 818-26. PMID 21946277 DOI: 10.1038/Nchembio.670 |
0.825 |
|
| 2011 |
Taldone T, Gomes-DaGama EM, Zong H, Sen S, Alpaugh ML, Zatorska D, Alonso-Sabadell R, Guzman ML, Chiosis G. Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy. Bioorganic & Medicinal Chemistry Letters. 21: 5347-52. PMID 21802945 DOI: 10.1016/J.Bmcl.2011.07.026 |
0.38 |
|
| 2011 |
Taldone T, Zatorska D, Patel PD, Zong H, Rodina A, Ahn JH, Moulick K, Guzman ML, Chiosis G. Design, synthesis, and evaluation of small molecule Hsp90 probes. Bioorganic & Medicinal Chemistry. 19: 2603-14. PMID 21459002 DOI: 10.1016/J.Bmc.2011.03.013 |
0.811 |
|
| 2011 |
Breinig M, Mayer P, Harjung A, Goeppert B, Malz M, Penzel R, Neumann O, Hartmann A, Dienemann H, Giaccone G, Schirmacher P, Kern MA, Chiosis G, Rieker RJ. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2237-49. PMID 21372220 DOI: 10.1158/1078-0432.Ccr-10-1689 |
0.403 |
|
| 2011 |
Ahn JH, Luo W, Kim J, Rodina A, Clement CC, Aguirre J, Sun W, Kang Y, Maharaj R, Moulick K, Zatorska D, Kokoszka M, Brodsky JL, Chiosis G. Design of a flexible cell-based assay for the evaluation of heat shock protein 70 expression modulators. Assay and Drug Development Technologies. 9: 236-46. PMID 21133677 DOI: 10.1089/Adt.2010.0327 |
0.824 |
|
| 2011 |
Zong H, Taldone T, Ahn JH, Brennan S, De Leon JP, Becker MW, Roboz GJ, Chiosis G, Guzman ML. FLT3-ITD+ AML Blast, Progenitor and Stem Cell Populations Demonstrate Higher Sensitivity to the Hsp90 Inhibitor PU-H71, Blood. 118: 3500-3500. DOI: 10.1182/Blood.V118.21.3500.3500 |
0.453 |
|
| 2011 |
Rico JF, Sharma KK, Kang Y, Taldone T, Patel H, Brennan S, Zong H, Becker MW, Roboz GJ, Chiosis G, Guzman ML. HSP70 Inhibitor, YK5, Ablates Blast, Progenitor and Stem Cell Populations in Primary Acute Myelogenous Leukemia Cells Blood. 118: 2493-2493. DOI: 10.1182/Blood.V118.21.2493.2493 |
0.412 |
|
| 2011 |
Sharma KK, Rico JF, Hassane DC, Chiosis G, Guzman ML. Dysregulated Expression of HSP70 Isoforms in Acute Myelogenous Leukemia (AML) Blood. 118: 1370-1370. DOI: 10.1182/Blood.V118.21.1370.1370 |
0.506 |
|
| 2011 |
Rodina A, Kang Y, Taldone T, Patel H, Patel P, Caldas-Lopes E, Erdjument-Bromage H, Guzman M, Young JC, Melnick A, Chiosis G. Abstract 2579: YK5, a small molecule inhibitor of Hsp70 and Hsc70, reveals a multifaceted role for the Hsp70 chaperones in regulating oncogenic and non-oncogenic addiction of tumors Cancer Research. 71: 2579-2579. DOI: 10.1158/1538-7445.Am2011-2579 |
0.572 |
|
| 2011 |
Usmani S, Bona R, Chiosis G. 601 The Antimyeloma Activity of PU-H71, a Novel Purine Scaffold HSP90 Inhibitor, is via Inhibition of Both HSP90A and HSP90B1 Clinical Lymphoma Myeloma and Leukemia. 11: S129-S130. DOI: 10.1016/J.Clml.2011.05.024 |
0.458 |
|
| 2010 |
Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA, Bhalla K, Gascoyne RD, Marra M, Chiosis G, Melnick A. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. The Journal of Clinical Investigation. 120: 4569-82. PMID 21041953 DOI: 10.1172/Jci42869 |
0.432 |
|
| 2010 |
Usmani SZ, Bona RD, Chiosis G, Li Z. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. Journal of Hematology & Oncology. 3: 40. PMID 20977755 DOI: 10.1186/1756-8722-3-40 |
0.544 |
|
| 2010 |
Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, ... ... Chiosis G, et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans Journal of Clinical Investigation. 120: 3578-3593. PMID 20852385 DOI: 10.1172/Jci42442 |
0.459 |
|
| 2010 |
Taldone T, Gillan V, Sun W, Rodina A, Patel P, Maitland K, O'Neill K, Chiosis G, Devaney E. Assay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90. Plos Neglected Tropical Diseases. 4: e714. PMID 20559560 DOI: 10.1371/Journal.Pntd.0000714 |
0.45 |
|
| 2010 |
Luo W, Sun W, Taldone T, Rodina A, Chiosis G. Heat shock protein 90 in neurodegenerative diseases. Molecular Neurodegeneration. 5: 24. PMID 20525284 DOI: 10.1186/1750-1326-5-24 |
0.514 |
|
| 2010 |
Wrona IE, Gozman A, Taldone T, Chiosis G, Panek JS. Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: Potent inhibitors of heat shock protein 90 Journal of Organic Chemistry. 75: 2820-2835. PMID 20392070 DOI: 10.1021/Jo1000109 |
0.429 |
|
| 2010 |
Holland JP, Caldas-Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Chiosis G, Lewis JS. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. Plos One. 5: e8859. PMID 20111600 DOI: 10.1371/Journal.Pone.0008859 |
0.463 |
|
| 2010 |
Usmani SZ, Bona RD, Chiosis G, Li Z. Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold HSP90 inhibitor. Journal of Clinical Oncology. 28: 8141-8141. DOI: 10.1200/Jco.2010.28.15_Suppl.8141 |
0.496 |
|
| 2010 |
Nayar U, Lu P, Vider J, Cerchietti L, Chiosis G, Wang L, Blasberg R, Cesarman E. Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma Infectious Agents and Cancer. 5. DOI: 10.1186/1750-9378-5-S1-A36 |
0.531 |
|
| 2010 |
Lopes EC, Gozman A, Taldone T, Ahn J, Marubayashi S, Rudin C, Levine RL, Nimer S, Chiosis G. Determinants of Apoptotic Sensitivity to HSP90 Inhibition In Acute Myeloid Leukemia Blood. 116: 2159-2159. DOI: 10.1182/Blood.V116.21.2159.2159 |
0.54 |
|
| 2010 |
Lopes EC, Bos P, Peinado H, Cerchietti L, Lavotshkin S, Melnick A, Lyden D, Chiosis G. Abstract 5766: The Hsp90 inhibitor PU-H71 is a potent suppressor of metastasis in triple-negative breast cancer models Cancer Research. 70: 5766-5766. DOI: 10.1158/1538-7445.Am10-5766 |
0.467 |
|
| 2010 |
Rodina A, Kang Y, Maharaj R, Gozman A, Taldone T, Cerchietti L, Wong MJH, Baaklini I, Caldas-Lopes E, Clement CC, Brodsky J, Erdjument-Bromage H, Ma Y, Melnick A, Young JC, ... Chiosis G, et al. Abstract 5463: YK5, a novel dual Hsc70 and Hsp70 inhibitor, is selective for tumor Hsp70 and has potent but selective activity in cancer cells Cancer Research. 70: 5463-5463. DOI: 10.1158/1538-7445.Am10-5463 |
0.605 |
|
| 2010 |
Taldone T, Zatorska D, Kang Y, Chiosis G. A facile and efficient synthesis of d6-labeled PU-H71, a purine-scaffold Hsp90 inhibitor Journal of Labelled Compounds and Radiopharmaceuticals. 53: 47-49. DOI: 10.1002/Jlcr.1689 |
0.357 |
|
| 2009 |
Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature Medicine. 15: 1369-76. PMID 19966776 DOI: 10.1038/Nm.2059 |
0.53 |
|
| 2009 |
Taldone T, Chiosis G. Purine-scaffold Hsp90 inhibitors. Current Topics in Medicinal Chemistry. 9: 1436-46. PMID 19860732 DOI: 10.2174/156802609789895737 |
0.552 |
|
| 2009 |
Breinig M, Caldas-Lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G, Kern MA. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology (Baltimore, Md.). 50: 102-12. PMID 19441108 DOI: 10.1002/Hep.22912 |
0.496 |
|
| 2009 |
Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, ... ... Chiosis G, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America. 106: 8368-73. PMID 19416831 DOI: 10.1073/Pnas.0903392106 |
0.812 |
|
| 2009 |
Chiosis G, Keeton AB. Assay for isolation of inhibitors of her2-kinase expression. Methods in Molecular Biology (Clifton, N.J.). 486: 139-49. PMID 19347621 DOI: 10.1007/978-1-60327-545-3_10 |
0.404 |
|
| 2009 |
Tao H, Kang Y, Taldone T, Chiosis G. Microwave-assisted one step synthesis of 8-arylmethyl-9H-purin-6-amines. Bioorganic & Medicinal Chemistry Letters. 19: 415-7. PMID 19058963 DOI: 10.1016/J.Bmcl.2008.11.057 |
0.474 |
|
| 2009 |
Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorganic & Medicinal Chemistry. 17: 2225-35. PMID 19017562 DOI: 10.1016/J.Bmc.2008.10.087 |
0.486 |
|
| 2009 |
Koppikar P, Marubayashi S, Taldone T, Abdel-Wahab O, West N, Gozman A, Ahn J, Rodina A, Bhagwat N, Hedvat CV, Bradner JE, Chiosis G, Levine RL. Efficacy of the Novel Non-Quinone Based HSP-90 Inhibitor PU-H71 in JAK2V617F and MPLW515L-Induced Murine Models of Myeloproliferative Neoplasms. Blood. 114: 3898-3898. DOI: 10.1182/Blood.V114.22.3898.3898 |
0.473 |
|
| 2009 |
Holland JP, Caldas‐Lopes E, Divilov V, Longo VA, Taldone T, Zatorska D, Chiosis G, Lewis JS. Abstract A226: ImmunoPET with 89Zr‐DFO‐trastuzumab: Monitoring the pharmacodynamic effects on HER2/neu expression by Hsp90 inhibition in vivo Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A226 |
0.368 |
|
| 2008 |
Chiosis G, Kang Y, Sun W. Discovery and development of purine-scaffold Hsp90 inhibitors. Expert Opinion On Drug Discovery. 3: 99-114. PMID 23480142 DOI: 10.1517/17460441.3.1.99 |
0.535 |
|
| 2008 |
Luo W, Rodina A, Chiosis G. Heat shock protein 90: translation from cancer to Alzheimer's disease treatment? Bmc Neuroscience. 9: S7. PMID 19090995 DOI: 10.1186/1471-2202-9-S2-S7 |
0.5 |
|
| 2008 |
Lopes EC, Valls E, Figueroa ME, Mazur A, Meng FG, Chiosis G, Laird PW, Schreiber-Agus N, Greally JM, Prokhortchouk E, Melnick A. Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer Research. 68: 7258-63. PMID 18794111 DOI: 10.1158/0008-5472.Can-08-0344 |
0.342 |
|
| 2008 |
Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Current Opinion in Pharmacology. 8: 370-4. PMID 18644253 DOI: 10.1016/J.Coph.2008.06.015 |
0.478 |
|
| 2008 |
Ganesh T, Min J, Thepchatri P, Du Y, Li L, Lewis I, Wilson L, Fu H, Chiosis G, Dingledine R, Liotta D, Snyder JP, Sun A. Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling. Bioorganic & Medicinal Chemistry. 16: 6903-10. PMID 18571929 DOI: 10.1016/J.Bmc.2008.05.047 |
0.546 |
|
| 2008 |
Goeckeler JL, Petruso AP, Aguirre J, Clement CC, Chiosis G, Brodsky JL. The yeast Hsp110, Sse1p, exhibits high-affinity peptide binding. Febs Letters. 582: 2393-6. PMID 18539149 DOI: 10.1016/J.Febslet.2008.05.047 |
0.372 |
|
| 2008 |
Kang Y, Taldone T, Clement CC, Fewell SW, Aguirre J, Brodsky JL, Chiosis G. Design of a fluorescence polarization assay platform for the study of human Hsp70. Bioorganic & Medicinal Chemistry Letters. 18: 3749-51. PMID 18515098 DOI: 10.1016/J.Bmcl.2008.05.046 |
0.499 |
|
| 2008 |
Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ, Moore DJ, Dawson TM, Dawson VL, Chiosis G, Cookson MR, et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 3384-91. PMID 18367605 DOI: 10.1523/Jneurosci.0185-08.2008 |
0.428 |
|
| 2008 |
Didelot C, Lanneau D, Brunet M, Bouchot A, Cartier J, Jacquel A, Ducoroy P, Cathelin S, Decologne N, Chiosis G, Dubrez-Daloz L, Solary E, Garrido C. Interaction of heat-shock protein 90β isoform (HSP90β) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation Cell Death and Differentiation. 15: 859-866. PMID 18239673 DOI: 10.1038/Sj.Cdd.4402320 |
0.462 |
|
| 2008 |
Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discovery Today. 13: 38-43. PMID 18190862 DOI: 10.1016/J.Drudis.2007.10.007 |
0.504 |
|
| 2008 |
Chan CT, Paulmurugan R, Gheysens OS, Kim J, Chiosis G, Gambhir SS. Molecular imaging of the efficacy of heat shock protein 90 inhibitors in living subjects. Cancer Research. 68: 216-26. PMID 18172314 DOI: 10.1158/0008-5472.Can-07-2268 |
0.466 |
|
| 2008 |
Lopes EC, Cerchietti L, Yang SN, Melnick A, Chiosis G. Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma Blood. 112: 602-602. DOI: 10.1182/Blood.V112.11.602.602 |
0.442 |
|
| 2007 |
Didelot C, Lanneau D, Brunet M, Joly AL, De Thonel A, Chiosis G, Garrido C. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Current Medicinal Chemistry. 14: 2839-47. PMID 18045130 DOI: 10.2174/092986707782360079 |
0.551 |
|
| 2007 |
Du Y, Moulick K, Rodina A, Aguirre J, Felts S, Dingledine R, Fu H, Chiosis G. High-throughput screening fluorescence polarization assay for tumor-specific Hsp90. Journal of Biomolecular Screening. 12: 915-24. PMID 17942784 DOI: 10.1177/1087057107306067 |
0.81 |
|
| 2007 |
Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A, Litz J, Clement CC, Kang Y, She Y, Wu N, Felts S, Wipf P, Massague J, Jiang X, ... ... Chiosis G, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nature Chemical Biology. 3: 498-507. PMID 17603540 DOI: 10.1038/Nchembio.2007.10 |
0.805 |
|
| 2007 |
Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proceedings of the National Academy of Sciences of the United States of America. 104: 9511-6. PMID 17517623 DOI: 10.1073/Pnas.0701055104 |
0.796 |
|
| 2007 |
Varticovski L, Wright MH, Caldas-Lopes E, Chiosis G, Robles AI. Synergy of the Purine-Scaffold HSP90 Inhibitor, PU-H71, with Doxorubicin in Non-Hodgkin’s Lymphoma Cell Lines. Blood. 110: 1399-1399. DOI: 10.1182/Blood.V110.11.1399.1399 |
0.502 |
|
| 2006 |
Chiosis G, Neckers L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. Acs Chemical Biology. 1: 279-84. PMID 17163756 DOI: 10.1021/Cb600224W |
0.414 |
|
| 2006 |
Chiosis G, Tao H. Purine-scaffold Hsp90 inhibitors. Idrugs : the Investigational Drugs Journal. 9: 778-82. PMID 17096299 |
0.419 |
|
| 2006 |
Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 10: 321-30. PMID 17010675 DOI: 10.1016/J.Ccr.2006.09.005 |
0.436 |
|
| 2006 |
Immormino RM, Kang Y, Chiosis G, Gewirth DT. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. Journal of Medicinal Chemistry. 49: 4953-60. PMID 16884307 DOI: 10.1021/Jm060297X |
0.499 |
|
| 2006 |
Brodsky JL, Chiosis G. Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. Current Topics in Medicinal Chemistry. 6: 1215-25. PMID 16842158 DOI: 10.2174/156802606777811997 |
0.529 |
|
| 2006 |
Chiosis G. Discovery and development of purine-scaffold Hsp90 inhibitors. Current Topics in Medicinal Chemistry. 6: 1183-91. PMID 16842155 DOI: 10.2174/156802606777812013 |
0.528 |
|
| 2006 |
Moulick K, Clement CC, Aguirre J, Kim J, Kang Y, Felts S, Chiosis G. Synthesis of a red-shifted fluorescence polarization probe for Hsp90. Bioorganic & Medicinal Chemistry Letters. 16: 4515-8. PMID 16797988 DOI: 10.1016/J.Bmcl.2006.06.025 |
0.754 |
|
| 2006 |
Chiosis G, Caldas Lopes E, Solit D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Current Opinion in Investigational Drugs (London, England : 2000). 7: 534-41. PMID 16784024 |
0.468 |
|
| 2006 |
Chu F, Maynard JC, Chiosis G, Nicchitta CV, Burlingame AL. Identification of novel quaternary domain interactions in the Hsp90 chaperone, GRP94. Protein Science : a Publication of the Protein Society. 15: 1260-9. PMID 16731965 DOI: 10.1110/Ps.052065106 |
0.359 |
|
| 2006 |
Chiosis G, Aguirre J, Nicchitta CV. Synthesis of Hsp90 dimerization modulators. Bioorganic & Medicinal Chemistry Letters. 16: 3529-32. PMID 16621545 DOI: 10.1016/J.Bmcl.2006.03.092 |
0.462 |
|
| 2006 |
Chiosis G, Rodina A, Moulick K. Emerging Hsp90 inhibitors: from discovery to clinic. Anti-Cancer Agents in Medicinal Chemistry. 6: 1-8. PMID 16475922 DOI: 10.2174/187152006774755483 |
0.829 |
|
| 2006 |
De Martino G, Edler MC, La Regina G, Coluccia A, Barbera MC, Barrow D, Nicholson RI, Chiosis G, Brancale A, Hamel E, Artico M, Silvestri R. New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. Journal of Medicinal Chemistry. 49: 947-54. PMID 16451061 DOI: 10.1021/Jm050809S |
0.358 |
|
| 2006 |
Chiosis G. Targeting chaperones in transformed systems--a focus on Hsp90 and cancer. Expert Opinion On Therapeutic Targets. 10: 37-50. PMID 16441227 DOI: 10.1517/14728222.10.1.37 |
0.558 |
|
| 2006 |
He H, Zatorska D, Kim J, Aguirre J, Llauger L, She Y, Wu N, Immormino RM, Gewirth DT, Chiosis G. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. Journal of Medicinal Chemistry. 49: 381-90. PMID 16392823 DOI: 10.1021/Jm0508078 |
0.557 |
|
| 2006 |
Chiosis G, Rodina A, Kim J, Aguirre J, Moulick K, Lopes EC, Wu N, She Y. 419 POSTER Defining Hsp90 as inhibitor of apoptosis in small cell lung cancer European Journal of Cancer Supplements. 4: 128. DOI: 10.1016/S1359-6349(06)70424-4 |
0.79 |
|
| 2005 |
Chiosis G, Brodsky JL. Small molecule microarrays: from proteins to mammalian cells - are we there yet? Trends in Biotechnology. 23: 271-4. PMID 15922078 DOI: 10.1016/J.Tibtech.2005.03.011 |
0.314 |
|
| 2005 |
Llauger L, He H, Kim J, Aguirre J, Rosen N, Peters U, Davies P, Chiosis G. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. Journal of Medicinal Chemistry. 48: 2892-905. PMID 15828828 DOI: 10.1021/Jm049012B |
0.558 |
|
| 2004 |
Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discovery Today. 9: 881-8. PMID 15475321 DOI: 10.1016/S1359-6446(04)03245-3 |
0.532 |
|
| 2004 |
Kim J, Felts S, Llauger L, He H, Huezo H, Rosen N, Chiosis G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. Journal of Biomolecular Screening. 9: 375-81. PMID 15296636 DOI: 10.1177/1087057104265995 |
0.483 |
|
| 2004 |
Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P, Chiosis G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chemistry & Biology. 11: 787-97. PMID 15217612 DOI: 10.1016/J.Chembiol.2004.04.008 |
0.505 |
|
| 2003 |
Llauger-Bufi L, Felts SJ, Huezo H, Rosen N, Chiosis G. Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorganic & Medicinal Chemistry Letters. 13: 3975-8. PMID 14592488 DOI: 10.1016/J.Bmcl.2003.08.065 |
0.476 |
|
| 2003 |
Chiosis G, Lucas B, Huezo H, Solit D, Basso A, Rosen N. Development of purine-scaffold small molecule inhibitors of Hsp90. Current Cancer Drug Targets. 3: 371-6. PMID 14529388 DOI: 10.2174/1568009033481778 |
0.53 |
|
| 2003 |
Huezo H, Vilenchik M, Rosen N, Chiosis G. Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. Chemistry & Biology. 10: 629-34. PMID 12890536 DOI: 10.1016/S1074-5521(03)00144-3 |
0.379 |
|
| 2003 |
Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L. 17AAG: low target binding affinity and potent cell activity--finding an explanation. Molecular Cancer Therapeutics. 2: 123-9. PMID 12589029 |
0.336 |
|
| 2002 |
Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 100: 3041-4. PMID 12351420 DOI: 10.1182/Blood-2002-05-1361 |
0.424 |
|
| 2002 |
Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N. Development of a purine-scaffold novel class of hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase Bioorganic and Medicinal Chemistry. 10: 3555-3564. PMID 12213470 DOI: 10.1016/S0968-0896(02)00253-5 |
0.488 |
|
| 2002 |
Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. The Journal of Biological Chemistry. 277: 39858-66. PMID 12176997 DOI: 10.1074/Jbc.M206322200 |
0.492 |
|
| 2001 |
Chiosis G, Timaul MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, Rosen N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells Chemistry and Biology. 8: 289-299. PMID 11306353 DOI: 10.1016/S1074-5521(01)00015-1 |
0.485 |
|
| 2001 |
Chiosis G, Rosen N, Sepp-Lorenzino L. LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family Bioorganic and Medicinal Chemistry Letters. 11: 909-913. PMID 11294389 DOI: 10.1016/S0960-894X(01)00099-3 |
0.356 |
|
| Show low-probability matches. |